Benzinga
Benzinga
Benzinga
lunedì, settembre 14

Caris Life Sciences Inc

CAINASDAQ
Trade with Public
Trade with Public
$24.34
0.301.25%
In chiusura: Sep 10, 5:00 PM EST
$24.34
0.301.25%
Pre-mercato: 5:58 AM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoDividendiConfrontaOpzioniRapporto azionario

Caris Life Sciences Financials

Caris Life Sciences (CAI) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Caris Life Sciences Raises FY2026 Sales Guidance from $1.000B-$1.020B to $1.030B-$1.040B vs $1.003B Est

Caris Life Sciences (NASDAQ:CAI) raises FY2026 sales outlook from $1.000 billion-$1.020 billion to $1.030 billion-$1.040 billion vs $1.003 billion estimate.
Benzinga Newsdesk

PRO
Caris Life Sciences Q2 Sales $263.712M Beat $238.125M Estimate

Benzinga Newsdesk

PRO
Caris Life Sciences Affirms FY2026 Sales Guidance of $1.000B-$1.020B vs $1.007B Est

Caris Life Sciences (NASDAQ:CAI) affirms FY2026 sales outlook from $1.000 billion-$1.020 billion to $1.000 billion-$1.020 billion vs $1.007 billion estimate.
Benzinga Newsdesk

PRO
Caris Life Sciences Q1 Sales $216.174M Beat $210.292M Estimate

Caris Life Sciences (NASDAQ:CAI) reported quarterly sales of $216.174 million which beat the analyst consensus estimate of $210.292 million by 2.80 percent. This is a 78.78 percent increase over sales of $120.915
Benzinga Newsdesk

These Analysts Revise Their Forecasts On Caris Life Sciences Following Q4 Earnings

Avi Kapoor

Cancer Test Maker Caris Life Sciences Unveils Breakthrough In Early Cancer Detection, Profit Surprise

Caris Life Sciences stock jumps after earnings crush estimates, sales soar 125%, and cancer test data show strong early results.
Vandana Singh

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved